Ruxolitinib is known to delay lymphocyte maturation, a property leveraged clinically in graft-versus-host disease and myeloproliferative disorders where altered JAK-STAT signaling drives aberrant T cell proliferation. The gene discussed is SOAT1; the disease is myeloproliferative disorder.